Analyzing DexCom (DXCM) Stock Performance

Shares of DexCom have moved 4.1% today, and are now trading at a price of $72.38. In contrast, the S&P 500 index saw a 0.0% change. Today's trading volume is 3,678,476 compared to the stock's average volume of 5,902,771.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. Based in San Diego, United States the company has 9,500 full time employees and a market cap of $29,004,619,776.

The company is now trading -25.24% away from its average analyst target price of $96.82 per share. The 23 analysts following the stock have set target prices ranging from $75.0 to $120.0, and on average give DexCom a rating of buy.

Over the last 12 months DXCM shares have declined by -15.9%, which represents a difference of -54.9% when compared to the S&P 500. The stock's 52 week high is $142.0 per share and its 52 week low is $62.34. Based on DexCom's average net margin growth of 14.4% over the last 6 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 3,622,300 541,500 15 25.0
2022 2,909,800 341,200 12 33.33
2021 2,448,500 216,900 9 -67.86
2020 1,926,700 549,700 28 300.0
2019 1,476,000 101,100 7 158.33
2018 1,031,600 -127,100 -12
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS